Antimicrobial innovation: A current update and perspective on the antibiotic drug development pipeline

Liam J. Stephens, Melissa V. Werrett, Adam C. Sedgwick, Steven D. Bull, Philip C. Andrews

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


As bacteria continue to develop resistance to our existing treatment options, antibiotic innovation remains overlooked. If current trends continue, then we could face the stark reality of a postantibiotic era, whereby routine bacterial infections could once again become deadly. In light of a warning signaled by the WHO, a number of new initiatives have been established in the hope of reinvigorating the antibiotic drug development pipeline. In this perspective, we aim to summarize some of these initiatives and funding options, as well as providing an insight into the predicament that we face. Using clinical trials data, company website information and the most recent press releases, a current update of the antibiotic drug development pipeline is also included.

Original languageEnglish
Pages (from-to)2035-2065
Number of pages31
JournalFuture Medicinal Chemistry
Issue number22
Early online date10 Nov 2020
Publication statusPublished - 30 Nov 2020


  • antibiotic drug development pipeline
  • antimicrobial innovation
  • medicinal chemistry
  • postantibiotic era

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this